Alliance Pharma to divest 60% stake in Unigreg

04:01 EDT 17 Apr 2018 | Pharmaceutical Business Review

Alliance Pharma's subsidiary Alliance Pharmaceuticals has agreed to sell its 60% interest in non-core Unigreg to its joint venture partner Pacific Glory Development for a consideration of £2.9m.

Original Article: Alliance Pharma to divest 60% stake in Unigreg


More From BioPortfolio on "Alliance Pharma to divest 60% stake in Unigreg"

Quick Search


Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.

Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...